Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000390
Status:
COMPLETED
Last Update Posted:
2015-04-23
First Post:
2000-01-17
Brief Title:
Antidepressant Treatment of AIDS Related Depression
Sponsor:
GEIGY Pharmaceuticals
Organization:
National Institute of Mental Health NIMH
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2000-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the effectiveness treating AIDS related depression with imipramine hydrochloride
Depression syndromes are commonly associated with chronic disabling and fatal diseases Due to the relentless course of HIV infection there is a certain reluctance to treat the associated depression In other illness it has been proven that treating the depression often results in improvement of overall health status
This is a placebo controlled trial Half of the patients are given imipramine hydrochloride every day for 6 weeks Assessment is done by self reports and the Hamilton Depression Rating Scale Prior to entry all patients are given a psychiatric evaluation There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride
Depression syndromes are commonly associated with chronic disabling and fatal diseases Due to the relentless course of HIV infection there is a certain reluctance to treat the associated depression In other illness it has been proven that treating the depression often results in improvement of overall health status
This is a placebo controlled trial Half of the patients are given imipramine hydrochloride every day for 6 weeks Assessment is done by self reports and the Hamilton Depression Rating Scale Prior to entry all patients are given a psychiatric evaluation There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride
Detailed Description:
To test the effectiveness treating AIDS related depression with imipramine hydrochloride
Depression syndromes are commonly associated with chronic disabling and fatal diseases Due to the relentless course of HIV infection there is a certain reluctance to treat the associated depression In other illness it has been proven that treating the depression often results in improvement of overall health status
This is a placebo controlled trial Half of the patients are given imipramine hydrochloride every day for 6 weeks Assessment is done by self reports and the Hamilton Depression Rating Scale Prior to entry all patients are given a psychiatric evaluation There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride
Depression syndromes are commonly associated with chronic disabling and fatal diseases Due to the relentless course of HIV infection there is a certain reluctance to treat the associated depression In other illness it has been proven that treating the depression often results in improvement of overall health status
This is a placebo controlled trial Half of the patients are given imipramine hydrochloride every day for 6 weeks Assessment is done by self reports and the Hamilton Depression Rating Scale Prior to entry all patients are given a psychiatric evaluation There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 87-DEP | OTHER | GEIGY Pharmaceuticals | None |